Haryana Has No Report On Coronil Efficacy: RTI Reply

Gurugram : The Haryana’s AYUSH Department, which purchased ₹2.72 crore-worth of Ramdev’s Ayurvedic COVID-19 medicine ‘Coronil’ in May this year, is not in possession of any test reports to establish its efficacy, an RTI reply has revealed.

The department also does not have a record of those who have recovered from the use of the ‘medicine’.

The proposal for the purchase of Coronil was referred by the office of Chief Minister Manohar Lal as per a letter by Haryana Medical Services Corporation Limited, the RTI reply revealed.

Due to paucity of funds with the AYUSH Department, the drug was bought with funds from the Haryana Corona Relief Fund.

The set of documents shared by the department, in reply to the RTI application by Panipat-based activist P.P. Kapoor, revealed that the technical panel of the AYUSH Department met on May 18 and approved the purchase saying the composition and strength of Coronil was as per the recommendations for immunity boosting and “maybe finalised and it may also be suitable for Corona patients”.

The State had 83,161 active cases on the said date and the panel approved to buy one lakh Coronil kits as mentioned in the quote given by Divya Pharmacy. Some of the ingredients of the tablet includes Giloy, Ashwagandha, Tulsi, Mulethi, Marich, and Choti Pipal.

  • Related Posts

    PGIMS recalls drug amid probe into deaths

    The PGIMS authorities have directed all departments to immediately stop using a specific batch of injectable Propofol, an anaesthetic drug, and return the available stock to the central store. The…

    NPPA list brings little relief: No price cut for 25% cancer drugs

    Mumbai: Nearly one in four cancer drug packs in a revised price list issued by the National Pharmaceutical Pricing Authority (NPPA) has seen no reduction in maximum retail price (MRP),…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    PGIMS recalls drug amid probe into deaths

    PGIMS recalls drug amid probe into deaths

    NPPA list brings little relief: No price cut for 25% cancer drugs

    NPPA list brings little relief: No price cut for 25% cancer drugs

    Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

    Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

    For Aakash Healthcare, Community People are Apples of its Eyes

    For Aakash Healthcare, Community People are Apples of its Eyes

    Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

    Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

    Yashoda Medicity: Baby takes a Giant Step in just One Year

    Yashoda Medicity: Baby takes a Giant Step in just One Year